This study reports the detection of an activity that stimulates the development of a subclass of burst-forming unit-erythroid (BFU-E) progenitors giving rise to small bursts in semi-solid cultures established in the presence of saturating concentrations of erythropoietin. These progenitors are considered to be mature BFU-E. The activity is found in extracts from kidney cells and appears to be physiologically regulated as it was respectively enhanced and decreased in kidneys from anemic and polycythemic mice. The disappearance of activity in kidney-cell extracts during long-term polycythemia correlated with an accumu-E D BLOOD CELL production in vertebrates results R from the proliferation and differentiation of a sequence of progenitors arising from multipotential hematopoietic stem cells.' Two erythropoietic progenitor populations have been well characterized in the mouse: the burst-forming-uniterythroid (BFU-E) population contains immature progenitors giving rise, within 7 days, to large multicentric erythroid colonies, in semi-solid cultures, called bursts2; the colonyforming-unit-erythroid (CFU-E) population is composed of more mature progenitors forming colonies of 8 to 64 red cells within 48 hours.3
R from the proliferation and differentiation of a sequence of progenitors arising from multipotential hematopoietic stem cells.' Two erythropoietic progenitor populations have been well characterized in the mouse: the burst-forming-uniterythroid (BFU-E) population contains immature progenitors giving rise, within 7 days, to large multicentric erythroid colonies, in semi-solid cultures, called bursts2; the colonyforming-unit-erythroid (CFU-E) population is composed of more mature progenitors forming colonies of 8 to 64 red cells within 48 hours. 3 Two kinds of regulators control the differentiation of these erythropoietic progenitors. Erythropoietin (EPO), a hormone synthetized by the kidney: is required for CFU-E proliferation and differentiation3 whereas burst-promotingactivity (BPA) induces the development of BFU-E.5 This activity is shared by Interleukin-3 (IL-3), granulocytemacrophage-colony-stimulating-factor (GM-CSF) and Interleukin-4 (IL-4) .6- 9 Whereas EPO and IL-3 are the major erythroid growth factors in vitro, other factors can also modulate the development of erythroid progenitors. We have recently shown that mouse serum contains erythroid-enhancing activities, acting on CFU-E."
Patients suffering from chronic renal failure or anephric patients develop severe anemia and require regular blood transfusions with risk of hepatitis, iron-overload and sensitization to major or minor histocompatibility antigens. The recent availability of recombinant human erythropoietin has allowed treatment of these patients with this hormone with significant results.".'* However, the large quantities of EPO given to the patients were less effective than was the endogeneous EPO produced in those patients after renal transplantation.I2 Because these authors concluded that the restoration of renal function improves the erythropoietic response to erythropoietin, we made the assumption that kidney cells would secrete another erythroid factor that would complement erythropoietin action.
In this study, we report the presence of an erythropoietic activity in murine kidney cell lysates that predominantly stimulates the proliferation of mature BFU-E progenitors giving rise to small bursts of fewer than 15 erythroid subcolonies in semi-solid cultures. We have observed that this activity was regulated in vivo by the erythropoietic status of the donor, different from erythropoietin and other he- matopoietic factors sharing a burst-promoting activity. This activity was named mature burst-promoting activity (MBPA).
MATERIALS AND METHODS
C57BL/6 (6 to 8-week-old males or females) were obtained from IFFA-CREDO (L'Arbresle, France). They were rendered anemic by one daily intraperitoneal injection of phenylhydrazine (Merck, Darmstadt, FRG) (30 mg/kg) for three days (hematocrits <30%), and were killed three days after the last injection. Polycythemia was induced by two weekly injections of 500 pL of packed syngeneic red blood cells.
Purified native murine IL-3 was purchased from Genzyme (Boston, MA). The conditioned medium of WEHI-3B cell line: (a gift of Dr S. Sealand, Unicet, Dardilly, France), obtained as described in,I3 was also used as a source of IL-3. Purified human interleukin for DA cells (HILDA) with a specific activity of 40,000 U/mL was a gift of Dr Soulillou (Nantes, France). Porcine EPO (1,000 U/mg) was obtained from the Centre National de Transfusion Sanguine (Paris, France) and purified recombinant human erythropoietin (rhEPO) from Boehringer (Mannheim, FRG).
ROYET ET AL
anti-IL-4 MoAbs were used at a final concentration of 1/100.1/100 and 1 /400 respectively. in cultures of bone marrow cells containing 0.5 U/mL rhEPO and 50 U/mL mIL-3 or 100 U/mL rmGM-CSF or 100 U/mL rmlL-4.
Kidney cell Iysures. Kidneys were removed from anemic, normal or polycythemic mice and perfused with phosphate buffered saline (PBS) supplemented with 2% fetal bovine serum (FBS, Flow Labs.
Rockville. MD). They were fragmented using scissors and passed through a syringe setted with a 0.9 mm diameter necdle. The suspensions were then filtered through nylon mesh (125 pm). Cells were washed twice in PBS. enumerated. resuspended a t 2.5 x 10' cells/mL in a Tris-HCI 10 mmol/L pH 7. 4 10 ' mol/L hemin (Sigma) and 0.8% methylcellulose. Porcine EPO or rhEPO (0.5 U/mL) was added in the presence of WEHI-3 conditioned medium or purified mIL-3 as indicated and kidney cell lysate concentrations a s specified below. Both sources of EPO and IL-3 gave similar results. Cells were plated at a final concentration of 2 x 10' cells/mL in a volume of 500 pL into 16 mm diameter wells. Cultures were incubated for 7 days a t 37OC in a water-saturated atmosphere containing 5% C02. Bursts were counted without staining: small (fewer than I5 subcolonies) and large (more than 15 subcolonies) bursts were discriminated and were respectively ascribed to the development of mature BFU-E (mBFU-E) or immature BFU-E (IBFU-E) (Fig 1) .
Long-term bone marrow cell cultures were established essentially as described." In brief, IO6 C57BL/6 bone marrow cells were placed in IMDM containing 15% selected horse serum (Biosys). 5% FBS. 0.4 mg/mL human transferrin (Bochringer), 10 -6 mol/L hydrocortisone (Sigma) and antibiotics. They were allowed to adhere for I w e k . The culture Long-term bone murrow cell cultures (LTBMC).
-- 
RESULTS
Kidney cell lysates increase the number of small bursts. It is well known that bone marrow cells plated in the presence of IL-3 and EPO form pure erythroid bursts. These bursts are heterogeneous in size, ranging from a few to a hundred subcolonies (Fig 1) . This size variability is thought to reflect the maturation step of the progenitors giving rise to the bursts.
According to our working hypothesis that another factor intervenes in erythropoietic differentiation, we prepared kidney cell lysates from normal or anemic mice (NKCL and AKCL). Preliminary experiments showed that only small bursts developed in the presence of EPO alone; the number was significantly increased by the addition of 5% NKCL or AKCL (not shown). Large bursts were never seen in these conditions, in contrast to cultures stimulated with mIL-3 or WEHI-3B-conditioned medium. We also noted that CFU-E proliferation was not affected by NKCL or AKCL (not shown).
We then compared the effect of mIL-3 and AKCL addition to cultures established in the presence of increasing concentrations of rhEPO. We used AKCL because it was shown to be more potent than NKCL (see later). Results in Fig 2 are representative of two other experiments. In the presence of EPO only, the number of bursts increased with the EPO concentration and reached a plateau for 0.5 U/mL; this EPO concentration was used in all subsequent experiments. Moreover, we observed that only small bursts develop in these conditions. Addition of 5% AKCL increases significantly the number of bursts to a plateau of about twice the number of bursts counted in the presence of EPO alone. Only small bursts of fewer than 15 subcolonies were observed in these cultures. The addition of a saturating mIL-3 concentration (50 U/mL) to cultures also increased the number of bursts to values similar to those reached with AKCL. However, because small and large bursts develop in the cultures containing mIL-3, we conclude that AKCL stimulates mature BFU-E to a greater extent than does mIL-3.
The stimulating activity present in AKCL is not IL-3, IL-4, GM-CSF, HILDA, or EPO. A number of factors, such as IL-3, GM-CSF, IL-4, HILDA and EPO, are known to stimulate BFU-E growth. The effects of anti-IL-3, anti-GM-CSF and anti-IL-4 were therefore tested. Results are shown in Fig 3. In each case, the increase in burst-number due to the addition of JL-3, GM-CSF and IL-4 (introduced at plateau concentrations as determined in preliminary experiments) was blocked by their respective antibodies or by a mixture of them. Because the mixture of these antibodies showed no effect on the low number of bursts developing in the presence of EPO alone, or when any two of the antibodies were added to cultures containing the nonrelated growth factor (eg, anti-IL-4 and anti-GM-CSF with mIL-3), we concluded that the neutralizing effect was not relevant to a toxicity present in the different antibodies. We also concluded that the spontaneous growth of some bursts in cultures containing EPO alone was not due to endogeneous production of these growth factors. In contrast, no inhibition of the activity present in AKCL was observed using the mixture of the antibodies. The conclusion that this activity was neither IL-3 nor GM-CSF was reinforced by the fact that AKCL was unable to allow growth of FDC-P2 cells, an IL-3-dependent cell line, or to stimulate formation of myeloid colonies in semisolid cultures of bone marrow cells (not shown).
That the stimulation of BFU-E was not due to EPO stems from three sets of data. First, no EPO was detected in AKCL using a radioimmunoassay16 performed by Dr N. Casadevall (Cochin Hospital, Paris, France). Second, we were unable to stimulate CFU-E growth with AKCL in cultures of murine bone marrow cells established in the absence of EPO but containing 5% normal mouse serum, a technique able to detect concentrations of EPO t 1 0 mU/mL." Third, as shown in Fig 2, the burst-number increase in response to AKCL addition was still clearly evident in the presence of an optimal EPO concentration.
Finally, no HILDA activity was detected in our AKCL by Dr J.F. Moreau (Nantes, France) using the DA1 test.I8 In conclusion, these experiments demonstrate that the stimulating activity was not IL-3, TL-4, GM-CSF, HILDA/LIF or EPO.
Activity of kidney cell lysates as a function of the erythropoietic status of the donors. The dose-response curves for extracts of kidneys from anemic, normal and polycythemic mice are shown in Fig 4. We observed a significant increase in the number of small bursts when normal kidney cell lysates were introduced a t 5 or 10% into the cultures (P c .OS). At lower concentrations, NKCL was without effect on BFU-E development. In contrast, only 1% of AKCL was necessary to obtain a significant increase (P e .OS), and a maximal stimulation was obtained with 2% of AKCL (P e .02). A similar increase in AKCL prepared from mice rendered anemic by bleeding was also seen (not shown).
The addition of polycythemic kidney cell lysate (PKCL) did not increase the number of small bursts, as compared with cultures containing only EPO (P =-.OS). We conclude that, even when used at IO%, PKCL was unable to stimulate mBFU-E development in culture. However, it is to be noted that this result was obtained only with kidney cell extracts obtained from mice maintained for a t least one week a t 70% hematocrit values.
We then investigated whether this increase or decrease in kidney cell extract activity from anemic and polycythemic mice could provoke a modification in the bone marrow and spleen erythroid progenitor pools of the animals. Therefore, bone marrow and spleen cells from anemic and polycythemic mice were seeded in semi-solid culture supplemented with porcine EPO and WEHI-3-conditioned medium to allow the development of all the mBFU-E and iBFU-E.
As polycythemia progressed, the total number of mBFU-E greatly increased in bone marrow and spleen, especially a t the end of the treatment when kidney cell extracts became inactive, whereas the total number of iBFU-E did not show such variations (Fig 5) .
To establish whether the increase of the mBFU-E number in the bone marrow was due to the decrease of the burstpromoting-activity production by the kidney of polycythemic mice, we investigated the sensitivity of the mBFU-E to AKCL. We postulate that the mBFU-E accumulating in the bone marrow of polycythemic mice could not differentiate into CFU-E because of the absence of endogenous burst promoting activity, and that they represent a subpopulation of mBFU-E particularly sensitive to this activity.
We seeded bone marrow cells taken at various times of Changes in the number of mBFU-E and iBFU-E in bone marrow and spleen of mice during a long-term polycythemia. Cultures were established in the presence of 0.5 UlmL porcine €PO and 5% WEHI-3-conditioned medium. Mice were injected twice a week with 500 pL of packed syngenic red blood cells. On different days they were killed and spleen and bone marrow cells were plated in culture for BFU-E number evaluation. (A) number of BFU-E per spleen: (B) number of BFU-E for two tibiae. In A, the curve (0) represents the mean of hematocrits of three mice just before they were killed for erythroid progenitor cultures. The open and shaded columns represent respectively small and large bursts in bone marrow and spleen of three mice. Statistical significance of each value compared with erythroid progenitors of 21 normal mice was: a. NS; b, P < .05; c, P < .02; d. P < .01. Fig 5. polycythemia in the presence of EPO alone or EPO and AKCL. As shown in Fig 6, the number of mBFU-E that need only EPO to develop did not greatly increase during polycythemia. In contrast, there is an important accumulation of AKCL-sensitive BFU-E that may explain the overall increase of mBFU-E during polycythemia. Similar experiments with anemic mice did not show any modification of mBFU-E or iBFU-E in the bone marrow of the treated animals (not shown).
Eflect of AKCL in Iong-term bone marrow cell cultures.
It is well known that erythropoiesis is blocked a t an early stage in LTBMC.I9 However, we have recently developed the technical conditions that allow a sustained erythropoietic differentiation in long term-bone marrow cell cultures in response to EPO." In these cultures, the extent of erythropoietic differentiation was evaluated by the frequency of CFU-E in the cultures as a function of time. CFU-E appear within two days after the addition of EPO, which suggests that erythropoiesis could be blocked at a later stage than iBFU-E in unstimulated cultures. We reasoned that if AKCL could act on immediate precursors of CFU-E in semi-solid cultures, then it might also have an effect on CFU-E production in LTBMC, at least during the first days. LTBMC were then established as described in Materials and Methods and refed with fresh bone marrow cells, but the addition of EPO was delayed for a week, a delay necessary for the complete depletion of the late erythroid progenitors. Then 0.1 U/mL porcine EPO, in the presence or absence of AKCL (5%). was added to the cultures. Figure 7 shows that the number of CFU-E per 5 x IO4 cells of LTBMC was significantly increased in the cultures costimulated with EPO and AKCL in comparison with cultures stimulated with EPO alone. The stimulating effect was particulary marked at days 3 and 4, the difference being progressively reduced to become insignificant a t day 10.
DISCUSSION
Two major growth factors are known to stimulate erythroid progenitor proliferation and differentiation in vitro. Interleukin-36 acts at the stem cell level or CFU-mix level." It also promotes the growth of more differentiated progenitors such as CFU-GM and BFU-E, the granulocytemacrophage and erythroid progenitors Other growth factors such as GM-CSF,' HILDA" and IL-4: also exhibit a burst-promoting activity. Erythropoietin, the second main erythroid growth factor, allows growth and differentiation of late erythroid progenitors (CFU-E) to the terminal erythrocyte3; it also allows the growth of mBFU-E,*' this article.
We now report the detection of an erythroid activity that stimulates the growth of erythroid bursts in mouse kidney cell lysates. We have demonstrated by using specific antibodies or by direct dosage that AKCL did not contain IL-3, GM-CSF, IL-4, EPO and HILDA. Moreover, because 4 ) * * kidney cells did not express IL-1 the possibility that a production of GM-CSF (known to stimulate BFU-E) may occur in the cultures after stimulation of accessory cells by IL-1 can be ruled out. This possibility was also rejected by our unpublished observations that AKCL does stimulate the proliferation of mBFU-E in cultures of bone marrow cells depleted in adherent and T and B cells. EPA was described as stimulating BFU-E and CFU-E p r~l i f e r a t i o n~~ although not confirmed by other However, the apparent inability of NKCL or AKCL to stimulate CFU-E growth in our hands rules out the possibility that kidney extracts contain an EPA-like activity. We therefore suggest that AKCL exhibits a novel burst-promoting activity, which stimulates the development of a peculiar type of erythroid burst compared with those observed in IL-3-stimulated bone marrow cell cultures. Bursts obtained in cultures established in the presence of AKCL and EPO are rather homogeneous in size, ranging from 4 to 15 subcolonies. In contrast, cultures stimulated by IL-3 and EPO exhibit large bursts with more numerous and large subcolonies and also large myeloid colonies. In addition, we have observed that small bursts were hemoglobinized from the fifth or sixth day of the culture, whereas large hemoglobinized bursts were seen only after 7 to 8 days of culture. For these reasons, we have assumed that small bursts develop from an erythroid progenitor (mature BFU-E:
mBFU-E) intermediate between CFU-E and IBFU-E giving rise to large erythroid bursts (immature BFU-E:iBFU-E).
The most interesting results were obtained from extracts made from kidneys harvested from anemic, normal or polycythemic mice. The activity of these extracts were strictly correlated with the erythropoietic activities of the donors: low in polycythemic and high in anemic kidneys relative to the normals. This parallels findings for EPO, also produced by the kidney: the concentration of which is high in serum of anemic rats.26 Similarly, the EPO concentration was low in polycythemic and high in anemic humans.27 However, erythropoietin seems to be more rapidly produced than MBPA after the induction of anemia.28v29 In polycythemic animals, MBPA production decreases slowly, probably more slowly than that of erythropoietin, although no data are available a t this time about the kinetics of EPO decrease in those animals. Thus, although both erythropoietic factors appear to be regulated in a similar manner, as a function of the erythropoietic status of the animal, erythropoietin production seems to be more stringently regulated, indicating its possible effectiveness in the important role of day-to-day maintenance of the red cell c o~n t .~~.~~ The total number of iBFU-E and mBFU-E was studied in the bone marrow and the spleen of polycythemic mice: whereas iBFU-E did not vary greatly, the total number of mBFU-E was greatly increased when kidney cell extracts became less active and then inactive. This kinetics could be ascribed to either the decrease of MBPA or the absence of EPO. We also observed that CFU-E number in bone marrow of polycythemic mice decreased to a basal level within 4 days of treatment as previously reported by other In contrast, no change in mBFU-E was observed a t this time. These results suggest that the decrease in EPO levels in polycythemic mice mainly affects CFU-E number, whereas the later reduction in MBPA could result in the accumulation of mBFU-E. Moreover, we have shown that the mBFU-E that were accumulated in polycythemic mice were almost all MBPA-sensitive progenitors that need both EPO and MBPA to differentiate.
These results led us to postulate that the kidney produces an activity distinct from EPO, which may play a role in the regulation of erythropoiesis, because its production is regulated in concert with the erythropoietic status of the donor. This hypothesis was reinforced by our observations with the long-term bone marrow cell cultures that allow erythropoietic differentiation in vitro, and therefore are a powerful tool in studying the effects of hematopoietic growth factors. In these cultures, kidney cell extracts were shown to be able to stimulate erythroid differentiation in the presence of EPO.
The data reported in this article strongly suggest that, beside erythropoietin, another hematopoietic factor is produced by the kidney. Preliminary experiments with extracts of human and primate kidney cells seem to give similar results; if these observations are confirmed, they may be important in the treatment of anephric patients or patients with chronic renal failure. These patients are treated with repeated injections of erythropoietin, and a significant inFor personal use only. on October 23, 2017 . by guest www.bloodjournal.org From crease in the red cell count and hematocrit is readily observable. However, this procedure requires large quantities of erythropoietin.""* The characterization of a human factor similar to that of the mouse, and its purification and production on a large scale would permit a study of its effectiveness on the primate erythropoiesis, and especially its synergistic activity with erythropoietin.
In conclusion, we have detected in kidney cell extracts an erythropoietic activity that acts on a particular class of progenitors, the mBFU-E, and that appears to play a physiologic role in the erythropoietic process. We propose the term of mature burst promoting activity (MBPA) to define this activity.
